Photocure ASA Logo

Photocure ASA

Develops photodynamic pharmaceuticals and devices to enhance bladder cancer detection for urologists.

PHO | OL

Overview

Corporate Details

ISIN(s):
NO0010000045
LEI:
5967007LIEEXZXG8OW35
Country:
Norway
Address:
HOFFSVEIEN 4, 0275 OSLO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Photocure ASA is a specialty pharmaceutical company, self-described as 'The Bladder Cancer Company.' It develops and commercializes pharmaceuticals and medical devices based on its proprietary photodynamic technology platform. The company's core focus is on improving the diagnosis, treatment, and management of bladder cancer. Its flagship products, marketed as Hexvix® and Cysview®, are used in conjunction with Blue Light Cystoscopy to enhance the visualization and detection of cancerous tumors. Photocure targets the global urologic oncology community, including hospitals, clinics, and specialists, providing transformative solutions to improve patient outcomes.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 17:08
Regulatory News Service
Photocure and Intelligent Scopes Corporation partner on development of AI for b…
English 176.1 KB
2025-10-15 17:08
Regulatory News Service
Photocure and Intelligent Scopes Corporation partner on development of AI for b…
English 11.6 KB
2025-09-22 08:23
Director's Dealing
Photocure ASA - Share option grant - Attachment: 20250922_PHO_Primary_insider_n…
English 110.6 KB
2025-09-22 08:23
Remuneration Information
Photocure ASA - Share option grant - Attachment: Release.pdf
English 136.2 KB
2025-09-22 08:23
Remuneration Information
Photocure ASA - Share option grant
English 2.7 KB
2025-08-04 14:39
Regulatory News Service
Asieris: Cevira (APL-1702) NDA Advances to Second Round of Technical Review - A…
English 161.4 KB
2025-08-04 14:39
Regulatory News Service
Asieris: Cevira (APL-1702) NDA Advances to Second Round of Technical Review
English 4.1 KB
2025-07-22 08:00
Report Publication Announcement
Photocure ASA: Invitation to presentation of second quarter and first half year…
English 117.4 KB
2025-07-22 08:00
Report Publication Announcement
Photocure ASA: Invitation to presentation of second quarter and first half year…
English 2.5 KB
2025-06-23 14:55
Director's Dealing
Photocure ASA - Share option grant - Attachment: PHO_OSE_Primary_insider_notifi…
English 161.3 KB
2025-06-23 14:55
Remuneration Information
Photocure ASA - Share option grant - Attachment: Release.pdf
English 138.0 KB
2025-06-23 14:55
Remuneration Information
Photocure ASA - Share option grant
English 3.5 KB
2025-05-08 05:00
Investor Presentation
Photocure ASA: Results for the first quarter of 2025
English 1.2 MB
2025-05-08 05:00
Quarterly Report
Photocure ASA: Results for the first quarter of 2025
English 742.5 KB
2025-05-08 05:00
Earnings Release
Photocure ASA: Results for the first quarter of 2025
English 151.0 KB

Automate Your Workflow. Get a real-time feed of all Photocure ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Photocure ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Photocure ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.